Loading...

David P Richman

Title(s)Professor, Neurology
SchoolUniversity of California, Davis
Phone530-754-5006
vCardDownload vCard

    Collapse Research 
    Collapse Research Activities and Funding
    Antigen-specific treatment of myasthenia gravis: Chimeric autoantibody receptor T cells targeting autoimmune B cells
    NIH/NINDS R21NS104516Jun 15, 2018 - May 31, 2020
    Role: Principal Investigator
    Development of Animal Models of Anti-MuSK Myasthenia
    NIH/NINDS R21NS071325Sep 30, 2010 - Aug 31, 2013
    Role: Principal Investigator
    IX INTERNATIONAL CONFERENCE ON MYASTHENIA GRAVIS
    NIH/NINDS R13NS036137May 1, 1997 - Apr 30, 1998
    Role: Principal Investigator
    STRUCTURE/FUNCTION ANALYSIS OF ACCHR EPITOPES
    NIH/NINDS P01NS024304Jan 1, 1987 - Sep 30, 1992
    Role: Co-Principal Investigator
    PATHOGENIC MECHANISMS IN MYASTHENIA
    NIH/NINDS R01NS019779Jul 1, 1984 - Jun 30, 1997
    Role: Principal Investigator
    ANTIIDIOTYPIC ANTIBODIES IN MYASTHENIA
    NIH/NINDS R01NS015462Jul 1, 1979 - Mar 31, 1996
    Role: Principal Investigator

    Collapse ORNG Applications 
    Collapse Clinical Trials

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Raja SM, Sanders DB, Juel VC, Harati Y, Smith AG, Pascuzzi R, Richman DP, Wu A, Aleš KL, Jacobus LR, Jacobus DP, Guptill JT. Validation of the triple timed up-and-go test in Lambert-Eaton myasthenia. Muscle Nerve. 2019 Sep; 60(3):292-298. PMID: 31269226.
      View in: PubMed
    2. Lara MS, Afify A, Ellis MP, Phan CT, Richman DP, Riess JW. Immune Checkpoint Inhibitor-Induced Myasthenia Gravis in a Patient with Advanced NSCLC and Remote History of Thymoma. Clin Lung Cancer. 2019 Apr 19. PMID: 31085042.
      View in: PubMed
    3. Sanders DB, Harati Y, Juel VC, Lou JS, Marburger T, Pascuzzi RM, Peltier AC, Richman DP, Smith AG. Reply. Muscle Nerve. 2018 05; 57(5):E130-E131. PMID: 29406616.
      View in: PubMed
    4. Sanders DB, Juel VC, Harati Y, Smith AG, Peltier AC, Marburger T, Lou JS, Pascuzzi RM, Richman DP, Xie T, Demmel V, Jacobus LR, Aleš KL, Jacobus DP. 3,4-diaminopyridine base effectively treats the weakness of Lambert-Eaton myasthenia. Muscle Nerve. 2018 04; 57(4):561-568. PMID: 29280483.
      View in: PubMed
    5. Howard JF, Utsugisawa K, Benatar M, Murai H, Barohn RJ, Illa I, Jacob S, Vissing J, Burns TM, Kissel JT, Muppidi S, Nowak RJ, O'Brien F, Wang JJ, Mantegazza R. Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study. Lancet Neurol. 2017 12; 16(12):976-986. PMID: 29066163.
      View in: PubMed
    6. Thakkar N, Guptill JT, Aleš K, Jacobus D, Jacobus L, Peloquin C, Cohen-Wolkowiez M, Gonzalez D. Population Pharmacokinetics/Pharmacodynamics of 3,4-Diaminopyridine Free Base in Patients With Lambert-Eaton Myasthenia. CPT Pharmacometrics Syst Pharmacol. 2017 09; 6(9):625-634. PMID: 28623849.
      View in: PubMed
    7. Bissig D, Manjunath R, Traylor BR, Richman DP, Ng KL. Acute Stroke Despite Dabigatran Anticoagulation Treated with Idarucizumab and Intravenous Tissue Plasminogen Activator. J Stroke Cerebrovasc Dis. 2017 Jun; 26(6):e102-e104. PMID: 28416406.
      View in: PubMed
    8. Dimachkie MM, Abuzinadah AR, Barohn RJ, Oskarsson B, Rocke DM, Dengel K, Richman DP. Myasthenia gravis exacerbation after discontinuing mycophenolate: A single-center cohort study. Neurology. 2016 Nov 08; 87(19):2067-2068. PMID: 27821567.
      View in: PubMed
    9. Richman DP. Lipoprotein-like receptor 4 antibodies in myasthenia gravis: pathogenic or protective. Eur J Neurol. 2016 11; 23(11):1593-1594. PMID: 27753233.
      View in: PubMed
    10. Sanders DB, Wolfe GI, Benatar M, Evoli A, Gilhus NE, Illa I, Kuntz N, Massey JM, Melms A, Murai H, Nicolle M, Palace J, Richman DP, Verschuuren J, Narayanaswami P. International consensus guidance for management of myasthenia gravis: Executive summary. Neurology. 2016 Jul 26; 87(4):419-25. PMID: 27358333.
      View in: PubMed
    11. Oskarsson B, Rocke DM, Dengel K, Richman DP. Myasthenia gravis exacerbation after discontinuing mycophenolate: A single-center cohort study. Neurology. 2016 Mar 22; 86(12):1159-63. PMID: 26850977; PMCID: PMC4820129 [Available on 03/22/17].
    12. Biglan KM, Shoulson I, Kieburtz K, Oakes D, Kayson E, Shinaman MA, Zhao H, Romer M, Young A, Hersch S, Penney J, Marder K, Paulsen J, Quaid K, Siemers E, Tanner C, Mallonee W, Suter G, Dubinsky R, Gray C, Nance M, Bundlie S, Radtke D, Kostyk S, Baic C, Caress J, Walker F, Hunt V, O'Neill C, Chouinard S, Factor S, Greenamyre T, Wood-Siverio C, Corey-Bloom J, Song D, Peavy G, Moskowitz C, Wesson M, Samii A, Bird T, Lipe H, Blindauer K, Marshall F, Zimmerman C, Goldstein J, Rosas D, Novak P, Caviness J, Adler C, Duffy A, Wheelock V, Tempkin T, Richman D, Seeberger L, Albin R, Chou KL, Racette B, Perlmutter JS, Perlman S, Bordelon Y, Martin W, Wieler M, Leavitt B, Raymond L, Decolongon J, Clarke L, Jankovic J, Hunter C, Hauser RA, Sanchez-Ramos J, Furtado S, Suchowersky O, Klimek ML, Guttman M, Sethna R, Feigin A, Cox M, Shannon B, Percy A, Dure L, Harrison M, Johnson W, Higgins D, Molho E, Nickerson C, Evans S, Hobson D, Singer C, Galvez-Jimenez N, Shannon K, Comella C, Ross C, Saint-Hilaire MH, Testa C, Rosenblatt A, Hogarth P, Weiner W, Como P, Kumar R, Cotto C, Stout J, Brocht A, Watts A, Eberly S, Weaver C, Foroud T, Gusella J, MacDonald M, Myers R, Fahn S, Shults C. Clinical-Genetic Associations in the Prospective Huntington at Risk Observational Study (PHAROS): Implications for Clinical Trials. JAMA Neurol. 2016 Jan; 73(1):102-10. PMID: 26569098.
      View in: PubMed
    13. Burns TM, Smith GA, Allen JA, Amato AA, Arnold WD, Barohn R, Benatar M, Bird SJ, Bromberg M, Chahin N, Ciafaloni E, Cohen JA, Corse A, Crum BA, David WS, Dimberg E, Sousa EA, Donofrio PD, Dyck PJ, Engel AG, Ensrud ER, Ferrante M, Freimer M, Gable KL, Gibson S, Gilchrist JM, Goldstein JM, Gooch CL, Goodman BP, Gorelov D, Gospe SM, Goyal NA, Guidon AC, Guptill JT, Gutmann L, Gutmann L, Gwathmey K, Harati Y, Harper CM, Hehir MK, Hobson-Webb LD, Howard JF, Jackson CE, Johnson N, Jones SM, Juel VC, Kaminski HJ, Karam C, Kennelly KD, Khella S, Khoury J, Kincaid JC, Kissel JT, Kolb N, Lacomis D, Ladha S, Larriviere D, Lewis RA, Li Y, Litchy WJ, Logigian E, Lou JS, MacGowen DJ, Maselli R, Massey JM, Mauermann ML, Mathews KD, Meriggioli MN, Miller RG, Moon JS, Mozaffar T, Nations SP, Nowak RJ, Ostrow LW, Pascuzzi RM, Peltier A, Ruzhansky K, Richman DP, Ross MA, Rubin DI, Russell JA, Sachs GM, Salajegheh MK, Saperstein DS, Scelsa S, Selcen D, Shaibani A, Shieh PB, Silvestri NJ, Singleton JR, Smith BE, So YT, Solorzano G, Sorenson EJ, Srinivasen J, Tavee J, Tawil R, Thaisetthawatkul P, Thornton C, Trivedi J, Vernino S, Wang AK, Webb TA, Weiss MD, Windebank AJ, Wolfe GI. Editorial by concerned physicians: Unintended effect of the orphan drug act on the potential cost of 3,4-diaminopyridine. Muscle Nerve. 2016 Feb; 53(2):165-8. PMID: 26662952.
      View in: PubMed
    14. Richman DP. The Future of Research in Myasthenia. JAMA Neurol. 2015 Jul; 72(7):812-4. PMID: 26011044.
      View in: PubMed
    15. Renton AE, Pliner HA, Provenzano C, Evoli A, Ricciardi R, Nalls MA, Marangi G, Abramzon Y, Arepalli S, Chong S, Hernandez DG, Johnson JO, Bartoccioni E, Scuderi F, Maestri M, Gibbs JR, Errichiello E, Chiò A, Restagno G, Sabatelli M, Macek M, Scholz SW, Corse A, Chaudhry V, Benatar M, Barohn RJ, McVey A, Pasnoor M, Dimachkie MM, Rowin J, Kissel J, Freimer M, Kaminski HJ, Sanders DB, Lipscomb B, Massey JM, Chopra M, Howard JF, Koopman WJ, Nicolle MW, Pascuzzi RM, Pestronk A, Wulf C, Florence J, Blackmore D, Soloway A, Siddiqi Z, Muppidi S, Wolfe G, Richman D, Mezei MM, Jiwa T, Oger J, Drachman DB, Traynor BJ. A genome-wide association study of myasthenia gravis. JAMA Neurol. 2015 Apr; 72(4):396-404. PMID: 25643325.
      View in: PubMed
    16. Rostedt Punga A, Kaminski HJ, Richman DP, Benatar M. How clinical trials of myasthenia gravis can inform pre-clinical drug development. Exp Neurol. 2015 Aug; 270:78-81. PMID: 25592627.
      View in: PubMed
    17. Ha JC, Richman DP. Myasthenia gravis and related disorders: Pathology and molecular pathogenesis. Biochim Biophys Acta. 2015 Apr; 1852(4):651-7. PMID: 25486268.
      View in: PubMed
    18. Morell SW, Trinh VB, Gudipati E, Friend A, Page NA, Agius MA, Richman DP, Fairclough RH. Structural characterization of the main immunogenic region of the Torpedo acetylcholine receptor. Mol Immunol. 2014 Mar; 58(1):116-31. PMID: 24333757.
      View in: PubMed
    19. Kim SS, Richman DP, Johnson WO, Hald JK, Agius MA. Limited utility of current MRI criteria for distinguishing multiple sclerosis from common mimickers: primary and secondary CNS vasculitis, lupus and Sjogren's syndrome. Mult Scler. 2014 Jan; 20(1):57-63. PMID: 23736535.
      View in: PubMed
    20. Richman DP, Nishi K, Ferns MJ, Schnier J, Pytel P, Maselli RA, Agius MA. Animal models of antimuscle-specific kinase myasthenia. Ann N Y Acad Sci. 2012 Dec; 1274:140-7. PMID: 23252909; PMCID: PMC3915870.
    21. Skalsky AJ, Oskarsson B, Han JJ, Richman D. Current pharmacologic management in selected neuromuscular diseases. Phys Med Rehabil Clin N Am. 2012 Nov; 23(4):801-20. PMID: 23137738.
      View in: PubMed
    22. Richman DP, Yu Y, Lee TT, Tseng PY, Yu WP, Maselli RA, Tang CY, Chen TY. Dominantly inherited myotonia congenita resulting from a mutation that increases open probability of the muscle chloride channel CLC-1. Neuromolecular Med. 2012 Dec; 14(4):328-37. PMID: 22790975; PMCID: PMC3508202.
    23. Kim JY, Park KD, Richman DP. Treatment of myasthenia gravis based on its immunopathogenesis. J Clin Neurol. 2011 Dec; 7(4):173-83. PMID: 22259613; PMCID: PMC3259491.
    24. Richman DP. Antibodies to low density lipoprotein receptor-related protein 4 in seronegative myasthenia gravis. Arch Neurol. 2012 Apr; 69(4):434-5. PMID: 22158717; PMCID: PMC3903387.
    25. Richman DP, Nishi K, Morell SW, Chang JM, Ferns MJ, Wollmann RL, Maselli RA, Schnier J, Agius MA. Acute severe animal model of anti-muscle-specific kinase myasthenia: combined postsynaptic and presynaptic changes. Arch Neurol. 2012 Apr; 69(4):453-60. PMID: 22158720; PMCID: PMC3915865.
    26. Kim SS, Richman DP, Zamvil SS, Agius MA. Accelerated central nervous system autoimmunity in BAFF-receptor-deficient mice. J Neurol Sci. 2011 Jul 15; 306(1-2):9-15. PMID: 21529843; PMCID: PMC4172440.
    27. Wong VS, Adamczyk P, Dahlin B, Richman DP, Wheelock V. Cerebral venous sinus thrombosis presenting with auditory hallucinations and illusions. Cogn Behav Neurol. 2011 Mar; 24(1):40-2. PMID: 21467920.
      View in: PubMed
    28. Sanders DB, Hart IK, Mantegazza R, Shukla SS, Siddiqi ZA, De Baets MH, Melms A, Nicolle MW, Solomons N, Richman DP. An international, phase III, randomized trial of mycophenolate mofetil in myasthenia gravis. Neurology. 2008 Aug 05; 71(6):400-6. PMID: 18434638.
      View in: PubMed
    29. Anderson JA, Ng JJ, Bowe C, McDonald C, Richman DP, Wollmann RL, Maselli RA. Variable phenotypes associated with mutations in DOK7. Muscle Nerve. 2008 Apr; 37(4):448-56. PMID: 18161030.
      View in: PubMed
    30. O'Connor P, Miller D, Riester K, Yang M, Panzara M, Dalton C, Miszkiel K, Khan O, Rice G, Sheremata W. Relapse rates and enhancing lesions in a phase II trial of natalizumab in multiple sclerosis. Mult Scler. 2005 Oct; 11(5):568-72. PMID: 16193895.
      View in: PubMed
    31. Hogarth P, Kayson E, Kieburtz K, Marder K, Oakes D, Rosas D, Shoulson I, Wexler NS, Young AB, Zhao H. Interrater agreement in the assessment of motor manifestations of Huntington's disease. Mov Disord. 2005 Mar; 20(3):293-7. PMID: 15584032.
      View in: PubMed
    32. Bragdon AC. Treatment of autoimmune myasthenia gravis. Neurology. 2004 Sep 28; 63(6):1138-9; author reply 1138-9. PMID: 15452326.
      View in: PubMed
    33. Richman DP, Agius MA. Treatment of autoimmune myasthenia gravis. Neurology. 2003 Dec 23; 61(12):1652-61. PMID: 14694025.
      View in: PubMed
    34. Richman DP, Agius MA. Treatment principles in the management of autoimmune myasthenia gravis. Ann N Y Acad Sci. 2003 Sep; 998:457-72. PMID: 14592915.
      View in: PubMed
    35. Agius MA, Richman DP, Fairclough RH, Aarli J, Gilhus NE, Romi F. Three forms of immune myasthenia. Ann N Y Acad Sci. 2003 Sep; 998:453-6. PMID: 14592914.
      View in: PubMed
    36. Fairclough RH, Agius MA, Gudipati E, Silvian L, Hamaoka B, Beltzner CC, Lin MY, Chuang AR, Richman DP. Agonist-induced transitions of the acetylcholine receptor. Ann N Y Acad Sci. 2003 Sep; 998:101-13. PMID: 14592867.
      View in: PubMed
    37. Roberts PF, Venuta F, Rendina E, De Giacomo T, Coloni GF, Follette DM, Richman DP, Benfield JR. Thymectomy in the treatment of ocular myasthenia gravis. J Thorac Cardiovasc Surg. 2001 Sep; 122(3):562-8. PMID: 11547310.
      View in: PubMed
    38. Maselli RA, Kong DZ, Bowe CM, McDonald CM, Ellis WG, Agius MA, Gomez CM, Richman DP, Wollmann RL. Presynaptic congenital myasthenic syndrome due to quantal release deficiency. Neurology. 2001 Jul 24; 57(2):279-89. PMID: 11468313.
      View in: PubMed
    39. Fairclough RH, Twaddle GM, Gudipati E, Lin MY, Richman DP. Differential surface accessibility of alpha(187-199) in the Torpedo acetylcholine receptor alpha subunits. J Mol Biol. 1998 Sep 18; 282(2):317-30. PMID: 9735290.
      View in: PubMed
    40. Fairclough RH, Twaddle GM, Gudipati E, Stone RJ, Richman DP, Burkwall DA, Josephs R. Mapping the mAb 383C epitope to alpha 2(187-199) of the Torpedo acetylcholine receptor on the three-dimensional model. J Mol Biol. 1998 Sep 18; 282(2):301-15. PMID: 9735289.
      View in: PubMed
    41. Weisberg L, Goldberg M. Quality improvement in neurology residency programs. Neurology. 1998 Sep; 51(3):922-3. PMID: 9748074.
      View in: PubMed
    42. Richman DP, Agius MA, Kirvan CA, Gomez CM, Fairclough RH, Dupont BL, Maselli RA. Antibody effector mechanisms in myasthenia gravis. The complement hypothesis. Ann N Y Acad Sci. 1998 May 13; 841:450-65. PMID: 9668274.
      View in: PubMed
    43. Fairclough RH, Gudipati E, Lin MY, Twaddle GM, Richman DP, Burkwall DA, Josephs R. A role for alpha(187-199) in the conversion of agonist binding energy to the opening of the acetylcholine receptor ion channel. Ann N Y Acad Sci. 1998 May 13; 841:87-92. PMID: 9668223.
      View in: PubMed
    44. Lin MY, Twaddle GM, Gudipati E, Richman DP, Fairclough RH. MAb 383C binds to the alpha-subunit of the acetylcholine receptor associated with the high-affinity tubocurarine site. Ann N Y Acad Sci. 1998 May 13; 841:101-3. PMID: 9668226.
      View in: PubMed
    45. Kirvan CA, Zhu S, Richman DP, Agius MA. Expression and initial characterization of recombinant antiacetylcholine receptor antibodies in experimental autoimmune myasthenia gravis. Ann N Y Acad Sci. 1998 May 13; 841:466-8. PMID: 9668275.
      View in: PubMed
    46. Bradley WG, Daube J, Mendell JR, Posner J, Richman D, Troost BT, Swift TR. Quality improvement in neurology residency programs. Report of the Quality Improvement Committee of the Association of University Professors of Neurology. Neurology. 1997 Nov; 49(5):1205-7. PMID: 9371894.
      View in: PubMed
    47. Maselli RA, Ellis W, Mandler RN, Sheikh F, Senton G, Knox S, Salari-Namin H, Agius M, Wollmann RL, Richman DP. Cluster of wound botulism in California: clinical, electrophysiologic, and pathologic study. Muscle Nerve. 1997 Oct; 20(10):1284-95. PMID: 9324085.
      View in: PubMed
    48. Mihovilovic M, Donnelly-Roberts D, Richman DP, Martinez-Carrion M. Pathogenesis of hyperacute experimental autoimmune myasthenia gravis. Acetylcholine receptor/cholinergic site/receptor function/autoimmunity. J Immunol. 1994 Jun 15; 152(12):5997-6002. PMID: 8207224.
      View in: PubMed
    49. Richman DP, Agius MA. Myasthenia gravis: pathogenesis and treatment. Semin Neurol. 1994 Jun; 14(2):106-10. PMID: 7984824.
      View in: PubMed
    50. Richman DP, Agius MA. Acquired myasthenia gravis. Immunopathology. Neurol Clin. 1994 May; 12(2):273-84. PMID: 8041342.
      View in: PubMed
    51. DeFilippi VJ, Richman DP, Ferguson MK. Transcervical thymectomy for myasthenia gravis. Ann Thorac Surg. 1994 Jan; 57(1):194-7. PMID: 8279889.
      View in: PubMed
    52. Maselli RA, Wollman RL, Leung C, Distad B, Palombi S, Richman DP, Salazar-Grueso EF, Roos RP. Neuromuscular transmission in amyotrophic lateral sclerosis. Muscle Nerve. 1993 Nov; 16(11):1193-203. PMID: 8105377.
      View in: PubMed
    53. Agius MA, Sanyal B, Richman DP. Molecular structure of a monoclonal antiacetylcholine receptor antibody and of a corresponding monoclonal antiidiotopic antibody. Ann N Y Acad Sci. 1993 Jun 21; 681:274-5. PMID: 8357167.
      View in: PubMed
    54. Xu Q, Fairclough RH, Richman DP. Effects of D-penicillamine on multiple immunogenic epitopes of the acetylcholine receptor. Ann N Y Acad Sci. 1993 Jun 21; 681:335-8. PMID: 7689309.
      View in: PubMed
    55. Xu Q, Twaddle GM, Richman DP, Fairclough RH. Characterization of the epitope of an antiacetylcholine receptor antibody that inhibits fifty percent of alpha-bungarotoxin binding. Ann N Y Acad Sci. 1993 Jun 21; 681:175-8. PMID: 7689304.
      View in: PubMed
    56. Richman DP, Wollmann RL, Maselli RA, Gomez CM, Corey AL, Agius MA, Fairclough RH. Effector mechanisms of myasthenic antibodies. Ann N Y Acad Sci. 1993 Jun 21; 681:264-73. PMID: 8357166.
      View in: PubMed
    57. Xu Q, Agius M, Gudipati E, Fairclough RH, Richman DP. An immunogenic self-peptide for T cells in mice with experimental myasthenia. Ann N Y Acad Sci. 1993 Jun 21; 681:1-4. PMID: 8357155.
      View in: PubMed
    58. Fairclough RH, Josephs R, Richman DP. Imaging ligand binding sites on the Torpedo acetylcholine receptor. Ann N Y Acad Sci. 1993 Jun 21; 681:113-25. PMID: 7689302.
      View in: PubMed
    59. Xu Q, Fairclough RH, Richman DP. Interaction of antiacetylcholine receptor monoclonal antibodies with the acetylcholine receptor. Ann N Y Acad Sci. 1993 Jun 21; 681:172-4. PMID: 7689303.
      View in: PubMed
    60. Maselli RA, Mass DP, Distad BJ, Richman DP. Anconeus muscle: a human muscle preparation suitable for in-vitro microelectrode studies. Muscle Nerve. 1991 Dec; 14(12):1189-92. PMID: 1662771.
      View in: PubMed
    61. Maselli RA, Richman DP, Wollmann RL. Inflammation at the neuromuscular junction in myasthenia gravis. Neurology. 1991 Sep; 41(9):1497-504. PMID: 1891103.
      View in: PubMed
    62. Richman DP, Fairclough RH, Xu Q, Agius MA. Noninflammatory immune mechanisms in diseases of the nervous system. Res Publ Assoc Res Nerv Ment Dis. 1990; 68:55-65. PMID: 2183319.
      View in: PubMed
    63. Chinchetru MA, Marquez J, Garcia-Borron JC, Richman DP, Martinez-Carrion M. Interaction of nicotinic acetylcholine receptor with two monoclonal antibodies recognizing different epitopes. Biochemistry. 1989 May 16; 28(10):4222-9. PMID: 2475163.
      View in: PubMed
    64. Maselli RA, Nelson DJ, Richman DP. Effects of a monoclonal anti-acetylcholine receptor antibody on the avian end-plate. J Physiol. 1989 Apr; 411:271-83. PMID: 2614725.
      View in: PubMed
    65. Maselli RA, Jow B, Richman DP, Nelson DJ. In vitro blockade of neuromuscular transmission by monoclonal anti-acetylcholine receptor antibodies. Ann N Y Acad Sci. 1988; 540:523-4. PMID: 2849901.
      View in: PubMed
    66. Agius MA, Geannopoulos CJ, Fairclough RH, Richman DP. Monoclonal anti-idiotopic antibodies against myasthenia-inducing anti-acetylcholine receptor monoclonal antibodies. Preponderance of nonparatope-directed antibodies affecting antigen binding. J Immunol. 1988 Jan 01; 140(1):62-8. PMID: 3257231.
      View in: PubMed
    67. Gomez CM, Richman DP. Chronic experimental autoimmune myasthenia gravis induced by monoclonal antibody to acetylcholine receptor: biochemical and electrophysiologic criteria. J Immunol. 1987 Jul 01; 139(1):73-6. PMID: 3035025.
      View in: PubMed
    68. Corey AL, Richman DP, Agius MA, Wollmann RL. Refractoriness to a second episode of experimental myasthenia gravis. Correlation with AChR concentration and morphologic appearance of the postsynaptic membrane. J Immunol. 1987 May 15; 138(10):3269-75. PMID: 3494763.
      View in: PubMed
    69. Mihovilovic M, Richman DP. Monoclonal antibodies as probes of the alpha-bungarotoxin and cholinergic binding regions of the acetylcholine receptor. J Biol Chem. 1987 Apr 15; 262(11):4978-86. PMID: 3558382.
      View in: PubMed
    70. Stefansson K, Dieperink ME, Richman DP, Marton LS. Sharing of epitopes by bacteria and the nicotinic acetylcholine receptor: a possible role in the pathogenesis of myasthenia gravis. Ann N Y Acad Sci. 1987; 505:451-60. PMID: 2446557.
      View in: PubMed
    71. Blair DA, Mihovilovic M, Agius MA, Fairclough RH, Richman DP. Human x human hybridomas from patients with myasthenia gravis: possible tools for idiotypic therapy for myasthenia. Ann N Y Acad Sci. 1987; 505:155-67. PMID: 3500665.
      View in: PubMed
    72. Agius MA, Richman DP. Suppression of development of experimental autoimmune myasthenia gravis with isogeneic monoclonal anti-idiotopic antibody. J Immunol. 1986 Oct 01; 137(7):2195-8. PMID: 3489757.
      View in: PubMed
    73. Blair DA, Richman DP, Taves CJ, Koethe S. Monoclonal antibodies to acetylcholine receptor secreted by human x human hybridomas derived from lymphocytes of a patient with myasthenia gravis. Immunol Invest. 1986 Jun; 15(4):351-64. PMID: 3759150.
      View in: PubMed
    74. Noronha A, Richman DP, Arnason BG. Multiple sclerosis: activated cells in cerebrospinal fluid in acute exacerbations. Ann Neurol. 1985 Dec; 18(6):722-5. PMID: 3841270.
      View in: PubMed
    75. Corey AL, Richman DP, Shuman CA, Gomez CM, Arnason BG. Use of monoclonal antiacetylcholine receptor antibodies to investigate the macrophage inflammation of acute experimental myasthenia gravis: refractoriness to a second episode of acute disease. Neurology. 1985 Oct; 35(10):1455-60. PMID: 3875805.
      View in: PubMed
    76. Shared antigens on acetylcholine receptor and bacterial proteins. N Engl J Med. 1985 Aug 08; 313(6):389-90. PMID: 2409443.
      View in: PubMed
    77. Gomez CM, Richman DP. Monoclonal anti-acetylcholine receptor antibodies with differing capacities to induce experimental autoimmune myasthenia gravis. J Immunol. 1985 Jul; 135(1):234-41. PMID: 3873489.
      View in: PubMed
    78. Chiu HC, Hsieh KH, Hung TP, Richman DP, Arnason BG. Effect of myasthenia serum and anti-acetylcholine receptor monoclonal antibody on the distributions of T-cell subsets in myasthenia patients and normal subjects. Asian Pac J Allergy Immunol. 1985 Jun; 3(1):30-6. PMID: 3925962.
      View in: PubMed
    79. Stefansson K, Dieperink ME, Richman DP, Gomez CM, Marton LS. Sharing of antigenic determinants between the nicotinic acetylcholine receptor and proteins in Escherichia coli, Proteus vulgaris, and Klebsiella pneumoniae. Possible role in the pathogenesis of myasthenia gravis. N Engl J Med. 1985 Jan 24; 312(4):221-5. PMID: 2578213.
      View in: PubMed
    80. Richman DP. Treatment of myasthenia gravis. J Neurol. 1985; 232(4):202-3. PMID: 4045512.
      View in: PubMed
    81. Mihovilovic M, Richman DP. Modification of alpha-bungarotoxin and cholinergic ligand-binding properties of Torpedo acetylcholine receptor by a monoclonal anti-acetylcholine receptor antibody. J Biol Chem. 1984 Dec 25; 259(24):15051-9. PMID: 6511786.
      View in: PubMed
    82. Atweh SF, Grayhack JJ, Richman DP. A cholinergic receptor site on murine lymphocytes with novel binding characteristics. Life Sci. 1984 Dec 10; 35(24):2459-69. PMID: 6334799.
      View in: PubMed
    83. Donnelly D, Mihovilovic M, Gonzalez-Ros JM, Ferragut JA, Richman D, Martinez-Carrion M. A noncholinergic site-directed monoclonal antibody can impair agonist-induced ion flux in Torpedo californica acetylcholine receptor. Proc Natl Acad Sci U S A. 1984 Dec; 81(24):7999-8003. PMID: 6096872.
      View in: PubMed
    84. Noronha A, Richman DP. Simultaneous cell surface phenotype and cell cycle analysis of lymphocytes by flow cytometry. J Histochem Cytochem. 1984 Aug; 32(8):821-6. PMID: 6205045.
      View in: PubMed
    85. Stefansson K, Molnar ML, Marton LS, Molnar GK, Mihovilovic M, Tripathi RC, Richman DP. Myelin-associated glycoprotein in human retina. Nature. 1984 Feb 9-15; 307(5951):548-50. PMID: 6198592.
      View in: PubMed
    86. Gomez CM, Wollmann RL, Richman DP. Induction of the morphologic changes of both acute and chronic experimental myasthenia by monoclonal antibody directed against acetylcholine receptor. Acta Neuropathol. 1984; 63(2):131-43. PMID: 6610275.
      View in: PubMed
    87. Gomez CM, Richman DP. Anti-acetylcholine receptor antibodies directed against the alpha-bungarotoxin binding site induce a unique form of experimental myasthenia. Proc Natl Acad Sci U S A. 1983 Jul; 80(13):4089-93. PMID: 6575398.
      View in: PubMed
    88. Yachnin S, Richman DP. Mevalonic acid in conjunction with help from neutrophils induces DNA synthesis and cell cycling in human peripheral blood lymphocytes. Cell Immunol. 1982 Sep 15; 72(2):248-62. PMID: 7151179.
      View in: PubMed
    89. Dropcho EJ, Richman DP, Antel JP, Arnason BG. Defective mitogenic responses in myasthenia gravis and multiple sclerosis. Ann Neurol. 1982 May; 11(5):456-62. PMID: 6980619.
      View in: PubMed
    90. Burres SA, Crayton JW, Gomez CM, Richman DP. Myasthenia induced by monoclonal anti-acetylcholine receptor antibodies: clinical and electrophysiological aspects. Ann Neurol. 1981 Jun; 9(6):563-8. PMID: 6167199.
      View in: PubMed
    91. Burres SA, Kanter ME, Richman DP, Arnason BG. Studies on the pathophysiology of chronic D-penicillamine-induced myasthenia. Ann N Y Acad Sci. 1981; 377:640-51. PMID: 6951489.
      View in: PubMed
    92. Gomez CM, Richman DP, Burres SA, Arnason BG, Berman PW, Fitch FW. Monoclonal hybridoma anti-acetylcholine receptor antibodies: antibody specificity and effect of passive transfer. Ann N Y Acad Sci. 1981; 377:97-109. PMID: 6978667.
      View in: PubMed
    93. Richman DP, Antel JP, Burns JB, Arnason BG. Nicotinic acetylcholine receptor on human lymphocytes. Ann N Y Acad Sci. 1981; 377:427-35. PMID: 6951484.
      View in: PubMed
    94. Noronha AB, Richman DP, Arnason BG. Detection of in vivo stimulated cerebrospinal-fluid lymphocytes by flow cytometry in patients with multiple sclerosis. N Engl J Med. 1980 Sep 25; 303(13):713-7. PMID: 6157088.
      View in: PubMed
    95. Antel JP, Oger JJ, Dropcho E, Richman DP, Kuo HH, Arnason BG. Reduced T-lymphocyte cell reactivity as a function of human aging. Cell Immunol. 1980 Aug 15; 54(1):184-92. PMID: 6967772.
      View in: PubMed
    96. Richman DP, Gomez CM, Berman PW, Burres SA, Fitch FW, Arnason BG. Monoclonal anti-acetylcholine receptor antibodies can cause experimental myasthenia. Nature. 1980 Aug 14; 286(5774):738-9. PMID: 7412861.
      View in: PubMed
    97. Richman DP. Lymphocyte cell-cycle analysis by flow cytometry. Evidence for a specific postmitotic phase before return to G0. J Cell Biol. 1980 May; 85(2):459-65. PMID: 6154712.
      View in: PubMed
    98. Richman DP, Arnason BG. Nicotinic acetylcholine receptor: evidence for a functionally distinct receptor on human lymphocytes. Proc Natl Acad Sci U S A. 1979 Sep; 76(9):4632-5. PMID: 291991.
      View in: PubMed
    99. Gomez CM, Richman DP, Berman PW, Burres SA, Arnason BG, Fitch FW. Monoclonal antibodies against purified nicotinic acetylcholine receptor. Biochem Biophys Res Commun. 1979 May 28; 88(2):575-82. PMID: 465055.
      View in: PubMed
    100. Burres SA, Richman DP, Crayton JW, Arnason BG. Penicillamine-induced myasthenic responses in the guinea pig. Muscle Nerve. 1979 May-Jun; 2(3):186-90. PMID: 228188.
      View in: PubMed
    101. Richman DP, Antel JP, Patrick JW, Arnason BG. Cellular immunity to acetylcholine receptor in myasthenia gravis: relationship to histocompatibility type and antigenic site. Neurology. 1979 Mar; 29(3):291-6. PMID: 571972.
      View in: PubMed
    102. Antel JP, Richman DP, Medof ME, Arnason BG. Lymphocyte function and the role of regulator cells in multiple sclerosis. Neurology. 1978 Sep; 28(9 Pt 2):106-10. PMID: 309564.
      View in: PubMed
    103. Richman DP, Dropcho EJ, Antel JP, Arnason BG. Contrasting defects of T-lymphocyte mitogenic response in multiple sclerosis and myasthenia gravis. Trans Am Neurol Assoc. 1978; 103:191-3. PMID: 316215.
      View in: PubMed
    104. Malm TM. Letter: Lymphocyte stimulation by acetylcholine receptor in myasthenia gravis. N Engl J Med. 1976 Jul 22; 295(4):226. PMID: 1272356.
      View in: PubMed
    105. Richman DP, Patrick J, Arnason BG. Cellular immunity in myasthenia gravis. Response to purified acetylcholine receptor and autologous thymocytes. N Engl J Med. 1976 Mar 25; 294(13):694-8. PMID: 129705.
      View in: PubMed
    106. Antel JP, Richman DP, Arnason BG. Immunogenetics and amyotrophic lateral sclerosis. UCLA Forum Med Sci. 1976; (19):151-71. PMID: 1023469.
      View in: PubMed
    107. Richman DP, Stewart RM, Hutchinson JW, Caviness VS. Mechanical model of brain convolutional development. Science. 1975 Jul 04; 189(4196):18-21. PMID: 1135626.
      View in: PubMed
    108. Stewart RM, Richman DP, Caviness VS. Lissencephaly and Pachygyria: an architectonic and topographical analysis. Acta Neuropathol. 1975; 31(1):1-12. PMID: 1121923.
      View in: PubMed
    109. Richman DP, Stewart RM, Caviness VS. Cerebral microgyria in a 27-week fetus: an architectonic and topographic analysis. J Neuropathol Exp Neurol. 1974 Jul; 33(3):374-84. PMID: 4835115.
      View in: PubMed
    110. Relative frequency of the Hurler and Hunter syndromes. N Engl J Med. 1970 Dec 24; 283(26):1466-8. PMID: 4991513.
      View in: PubMed
    111. Arnason BG, Richman DP. Effect of oral contraceptives on experimental demyelinating disease. Arch Neurol. 1969 Jul; 21(1):103-8. PMID: 4977266.
      View in: PubMed
    112. Arnason BG, Richman DP. Effects of estrogen, progestin and combined estrogen-progestin oral contraceptive preparations on experimental allergic encephalomyelitis. Trans Am Neurol Assoc. 1969; 94:54-8. PMID: 5374490.
      View in: PubMed